Compare Heron Therapeutics Inc (HRTX) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Manhattan Associates Inc — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Manhattan Associates Inc trades at $161 (market cap $9.79B). The key difference: Manhattan Associates Inc is far larger — about 107× Heron Therapeutics Inc's market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | MANH | |
|---|---|---|
Market Cap | $91.46M | $9.79B |
Sector | Health | Technology |
52-Week High | $1.96 | $227.94 |
52-Week Low | $0.39 | $120.88 |
Enterprise Value | $189.36M | $9.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Manhattan Associates (MANH) trades at $165.51, up 1.42% today, with a bullish technical outlook supported by moving averages and strong support at $162. The company demonstrates robust fundamentals with a 19.68% net margin and consistent earnings beats in recent quarters. Analyst sentiment remains positive with 73% buy ratings and a $192.80 consensus target, though an ongoing legal investigation has generated negative news flow.
MANH presents a growth opportunity with high profitability and earnings momentum, but faces near-term risks from legal scrutiny and premium valuations. The stock's technical strength and fundamental performance support upside potential, though investors should weigh the legal overhang against strong operational execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
